Dr Fonesca highlights key factors in multiple myeloma treatment affecting patient quality of life.
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
Preserving quality of life is paramount when treating relapsed/refractory multiple myeloma (RRMM). Beyond managing acute toxicities from newer treatments like chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies, preventing long-term adverse events is crucial. Peripheral neuropathy, largely from bortezomib, remains highly problematic despite weekly subcutaneous dosing. Neuropathy harms day-to-day functioning, requires added medications, increases fall/fracture risks, etc. More vigilance is needed even for grade 1 neuropathy. Encouragingly, more trials now include quality of life and patient-reported outcomes to capture patient perspectives and drive change, like the shift from 12 days of high-dose dexamethasone to just 4 days.
Recent updates with idecabtagene vicleucel and CAR T-cell therapy also suggest quality of life benefits compared to other regimens with less frequent health care contact. As measures become more standardized, quality of life differences may further influence treatment selections. Anecdotally, patients report feeling better on CAR T-cell therapy with reduced trips, injections, and dexamethasone exposure. While balancing efficacy remains vital, optimizing quality of life is a key goal in myeloma.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
2 Commerce Drive
Cranbury, NJ 08512